SCHEMBL6203338

SCHEMBL6203338

CC(C)(C)OC(=O)N1CC=CCN1C(=O)OC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CTSK P43235 1/20 0.50
PREP P48147 1/20 0.45
USP2 O75604 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CHRM2 P08172 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
NR1H2 P55055 1/20 0.37
BCHE P06276 1/20 0.37
HPGD P15428 1/20 0.36
GPR119 Q8TDV5 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ESR2 Q92731 1/20 0.35
RECQL P46063 1/20 0.34
EPHX1 P07099 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6203340 0.92 CTSK (0.45) CTSKPREPUSP2SMN1; SMN2CHRM2
SCHEMBL6023105 0.89 CTSK (0.50) CTSKPREPUSP2SMN1; SMN2CHRM2
SCHEMBL6023110 0.84 CTSK (0.43) CTSKPREPUSP2SMN1; SMN2CHRM2
SCHEMBL29489783 0.82 CTSK (0.40) CTSKPREPUSP2SMN1; SMN2CHRM2
SCHEMBL222920 0.82 PREP (0.53) CTSKPREPUSP2SMN1; SMN2NR1H2
SCHEMBL3603586 0.79 CTSK (0.72) CTSKPREPUSP2SMN1; SMN2CHRM2
SCHEMBL900812 0.79 CTSK (0.67) CTSKPREPUSP2SMN1; SMN2CHRM2
SCHEMBL16586930 0.74 USP2 (0.41) CTSKPREPUSP2SMN1; SMN2CHRM2
SCHEMBL15414407 0.74 PREP (0.40) CTSKPREPUSP2SMN1; SMN2CHRM2
SCHEMBL173435 0.74 USP2 (0.49) CTSKPREPUSP2SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1257905-C Compounds for inhibiting the release of inflammatory cytokines PROCTER & GAMBLE (US) 2006-05-31 CN disclosed
EP-1427727-B1 COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES PROCTER & GAMBLE (US) 2005-01-26 EP disclosed
CN-1555375-A compounds that inhibit inflammatory cytokine release 2004-12-15 CN disclosed
US-6821971-B2 FOR PROPHYALXIS OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE (IBS), SEPTIC SHOCK, CARDIOPULMONARY DYSFUNCTION, ACUTE RESPIRATORY DISEASE, CACHEXIA THE PROCTER & GAMBLE COMPANY 2004-11-23 US disclosed
EP-1427727-A1 COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES THE PROCTER & GAMBLE COMPANY (US) 2004-06-16 EP disclosed
US-20030105084-A1 Compound which inhibit the release of inflammatory cytokines THE PROCTER & GAMBLE COMPANY 2003-06-05 US disclosed
WO-2003024970-A1 COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES THE PROCTER & GAMBLE COMPANY (US) 2003-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105084-A1 Compound which inhibit the release of inflammatory cytokines IL1B, IL1A, TNF CTSK 447/4885PREP 290/4885USP2 1990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.